Drug intelligence / Profile preview

AB-0531

Development stage: Preclinical
Lead developer: Alethia Biotherapeutics
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules

Overview

AB-0531 is an investigational immune checkpoint inhibitor developed by Alethia Biotherapeutics for the treatment of cancer. It is classified as an antineoplastic and immunotherapy agent, with its mechanism of action involving antibody-dependent cell cytotoxicity. As of April 2024, AB-0531 remains in preclinical development for oncology indications, specifically neoplasms/cancer. There are no reports of clinical trials or approvals to date[2][1].

Beyond the preview

Go deeper on AB-0531.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB-0531.

Explore the full profile